Cargando…

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma

The efficacy of melphalan (MEL) 140 mg/m(2) pre-transplant conditioning versus MEL 200 mg/m(2) for the elderly is still debated. We hypothesized that single-agent intravenous busulfan (BU) would show significant anti-myeloma efficacy and be better tolerated by elderly patients. A prospective 3+3 dos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radhakrishnan, Sabarinath V., Boyer, Michael, Sherwin, Catherine M., Zangari, Maurizio, Tricot, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923548/ https://www.ncbi.nlm.nih.gov/pubmed/31619057 http://dx.doi.org/10.1177/0963689719880541

Ejemplares similares

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment
por: Zhou, Shiyuan, et al.
Publicado: (2023)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
por: Guo, Wancheng, et al.
Publicado: (2023)

Effects of intravenous multiple busulfan injection on suppression of endogenous spermatogenesis in recipient stallion testes
por: Jung, Heejun, et al.
Publicado: (2021)

Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT
por: Berger, Karin, et al.
Publicado: (2015)

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen
por: Versluijs, A. Birgitta, et al.
Publicado: (2022)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Multiple myeloma presenting as CEA-producing rectal cancer
por: Talamo, Giampaolo, et al.
Publicado: (2010)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Gao, Fei, et al.
Publicado: (2021)

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft
por: Jullien, Maxime, et al.
Publicado: (2020)

Busulfan‐containing conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: A Taiwan observational study
por: Wang, Yu‐Hung, et al.
Publicado: (2021)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Use of Busulfan to Condition Mice for Bone Marrow Transplantation
por: Montecino-Rodriguez, Encarnacion, et al.
Publicado: (2020)

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation
por: Templin, Julia, et al.
Publicado: (2017)

Effect of GSTA1 Variants on Busulfan-Based Conditioning Regimen Prior to Allogenic Hematopoietic Stem-Cell Transplantation in Pediatric Asians
por: Nguyen, Ai-Hoc, et al.
Publicado: (2022)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Emerging agents and regimens for multiple myeloma
por: Yang, Yang, et al.
Publicado: (2020)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany
por: Basic, Edin, et al.
Publicado: (2020)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cp73epadfmliiiqh3pgu7cdq64